Literature DB >> 21524964

Mortality predictors of Pneumocystis jirovecii pneumonia in human immunodeficiency virus-infected patients at presentation: Experience in a tertiary care hospital of northern Taiwan.

Hsiao-Wei Wang1, Cheng-Chih Lin, Chen-Feng Kuo, Chang-Pan Liu, Chun-Ming Lee.   

Abstract

BACKGROUND: Pneumocystis jirovecii pneumonia (PJP) remains the leading cause of opportunistic infections and deaths among human immunodeficiency virus (HIV)-infected patients. We would like to identify the predictors of mortality of these patients at initial presentation, and assist clinicians to aware the patients in risk of mortality earlier.
METHODS: From 1997 to 2009, adults with HIV infection and a discharge diagnosis of PJP at Mackay Memorial Hospital were included in this retrospective study. Patients' demographic data and laboratory data were analyzed by reviewing the medical records.
RESULTS: Eighty-five patients were included in this study. The overall mortality rate was 37.7%. Univariate analysis revealed several host factors significantly related to mortality, including age, systolic blood pressure, diastolic blood pressure, partial pressure of oxygen in arterial blood (PaO(2)), percentage of lymphocyte, percentage of CD4 lymphocyte, CD4 counts, serum total protein, serum albumin, and blood urea nitrogen. Multivariate analysis identified three independent predictors associated with mortality, i.e. systolic blood pressure ≤110 mmHg [adjusted odds ratio (AOR) 3.88; 95% confidence interval (CI) 1.17-12.83; p = 0.03], PaO(2) at room air ≤60 mmHg (AOR 4.97; 95% CI 1.34-18.23; p = 0.01), and lymphocytes ≤10% (AOR 8.19; 95% CI 1.48-45.36; p = 0.02). With these predictors, we can stratify patients into three groups with increasing risks for mortality, ≤one predictor (mortality rate 14%), any two predictors (47%), and three predictors (75%).
CONCLUSIONS: HIV-infected patients with PJP can be clinically stratified by three prognostic variables identified by multivariate analysis. Early recognition of patients in higher risk can assist clinicians to prevent rapid deterioration and seek for better outcomes.
Copyright © 2011. Published by Elsevier B.V.

Entities:  

Mesh:

Year:  2011        PMID: 21524964     DOI: 10.1016/j.jmii.2010.08.006

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  10 in total

Review 1.  Epidemiology and long-term survival in HIV-infected patients with Pneumocystis jirovecii pneumonia in the HAART era: experience in a university hospital and review of the literature.

Authors:  Cristina López-Sánchez; Vicenç Falcó; Joaquin Burgos; Jordi Navarro; María Teresa Martín; Adrià Curran; Lucía Miguel; Inma Ocaña; Esteve Ribera; Manel Crespo; Benito Almirante
Journal:  Medicine (Baltimore)       Date:  2015-03       Impact factor: 1.889

2.  Risk factors for mortality from pneumocystis carinii pneumonia (PCP) in non-HIV patients: a meta-analysis.

Authors:  Yao Liu; Lili Su; Shu-Juan Jiang; Hui Qu
Journal:  Oncotarget       Date:  2017-08-04

3.  Prognostic indicators in the World Health Organization's algorithm for seriously ill HIV-infected inpatients with suspected tuberculosis.

Authors:  Rulan Griesel; Annemie Stewart; Helen van der Plas; Welile Sikhondze; Marc Mendelson; Gary Maartens
Journal:  AIDS Res Ther       Date:  2018-02-12       Impact factor: 2.250

4.  Point-of-care lung ultrasound for diagnosis of Pneumocystis jirovecii pneumonia: notes from the field.

Authors:  Maria Teresa Giordani; Francesca Tamarozzi; Daniel Kaminstein; Enrico Brunetti; Tom Heller
Journal:  Crit Ultrasound J       Date:  2018-04-17

5.  Fast and Accurate Pneumocystis Pneumonia Diagnosis in Human Samples Using a Label-Free Plasmonic Biosensor.

Authors:  Olalla Calvo-Lozano; Anna Aviñó; Vicente Friaza; Alfonso Medina-Escuela; César S Huertas; Enrique J Calderón; Ramón Eritja; Laura M Lechuga
Journal:  Nanomaterials (Basel)       Date:  2020-06-26       Impact factor: 5.076

6.  An overview of Pneumocystis jirovecii pneumonia for the African generalist practitioner.

Authors:  I Govender; O M Maphasha; S Rangiah; C Steyn
Journal:  Afr Health Sci       Date:  2019-12       Impact factor: 0.927

7.  A Clinically Applicable Nomogram for Predicting the Risk of Invasive Mechanical Ventilation in Pneumocystis jirovecii Pneumonia.

Authors:  Rongjun Wan; Lu Bai; Yusheng Yan; Jianmin Li; Qingkai Luo; Hua Huang; Lingmei Huang; Zhi Xiang; Qing Luo; Zi Gu; Qing Guo; Pinhua Pan; Rongli Lu; Yimin Fang; Chengping Hu; Juan Jiang; Yuanyuan Li
Journal:  Front Cell Infect Microbiol       Date:  2022-03-10       Impact factor: 5.293

8.  Pneumocystis jirovecii genotype associated with increased death rate of HIV-infected patients with pneumonia.

Authors:  Meja Rabodonirina; Laetitia Vaillant; Patrick Taffé; Aimable Nahimana; René-Pierre Gillibert; Philippe Vanhems; Philippe M Hauser
Journal:  Emerg Infect Dis       Date:  2013-01       Impact factor: 6.883

9.  Relationship between Radiological Stages and Prognoses of Pneumocystis Pneumonia in Non-AIDS Immunocompromised Patients.

Authors:  Xiang-Dong Mu; Peng Jia; Li Gao; Li Su; Cheng Zhang; Ren-Gui Wang; Guang-Fa Wang
Journal:  Chin Med J (Engl)       Date:  2016-09-05       Impact factor: 2.628

10.  Trends in the Epidemiology and Outcomes of Pneumocystis Pneumonia among Human Immunodeficiency Virus (HIV) Hospitalizations.

Authors:  Kalaimani Elango; Mayuri Mudgal; Swetha Murthi; Prashanth Reddy Yella; Savan Nagrecha; Vedhapriya Srinivasan; Vijaykumar Sekar; Maria Koshy; Sathishkumar Ramalingam; Kulothungan Gunasekaran
Journal:  Int J Environ Res Public Health       Date:  2022-02-27       Impact factor: 3.390

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.